Basic Alesse Information

• INN (International Nonproprietary Name): Levonorgestrel and Ethinyl Estradiol
• Brand Names Available In United Kingdom: Alesse, Aviane, Altavera, Amethyst, Enpresse; variants with same INN marketed as Seasonique, Lutera, Lessina, Levlite and others (availability by national licence may vary)
• ATC Code: G03AA07
• Forms & Dosages: Oral tablet. Typical strength for Alesse 21/28 is 0.1 mg levonorgestrel + 0.02 mg ethinyl estradiol per active tablet. Pack formats: Alesse 21 (21 active) and Alesse 28 (21 active + 7 placebo).
• Manufacturers In United Kingdom: Original manufacturer listed as Pfizer/Wyeth; generic suppliers include Apotex, Teva and Sandoz (UK-specific manufacturer listings not specified)
• Registration Status In United Kingdom: Not specified
• OTC / Rx Classification: Prescription Only (Rx)

Latest Research Highlights

Patients worry about blood clots and whether the combined pill is still a safe option.

Recent UK and EU work from 2022–2025 continued to clarify the risk–benefit profile for low‑dose combined oral contraceptives containing levonorgestrel and ethinyl estradiol.

Cohort analyses and pooled studies confirm high contraceptive effectiveness with typical‑use failure rates lower than barrier methods when taken as directed.

Data show a small but measurable increase in venous thromboembolism risk compared with non‑users, yet the relative risk is lower for levonorgestrel‑containing COCs versus some newer progestogens.

NHS real‑world cohorts report that unscheduled bleeding and mood changes are common reasons for stopping the pill rather than contraceptive failure.

National pharmacovigilance updates from MHRA and EMA have highlighted the need to assess metabolic and hepatic contraindications before prescribing.

Practical summary table: effectiveness, VTE risk and discontinuation across key UK/EU studies 2022–25.

Clinical Effectiveness In The UK

People ask whether this pill actually stops ovulation reliably.

In UK practice, the levonorgestrel + ethinyl estradiol combination is a standard low‑dose COC routinely prescribed by GPs, sexual health clinics and private clinics.

NHS audit data and patient‑reported outcome studies indicate reliable ovulation suppression and good cycle control when one active tablet is taken daily as directed.

Discontinuation in NHS cohorts is most often linked to unscheduled bleeding, mood changes or perceived weight change rather than contraceptive failure.

MHRA and NICE guidance advise baseline assessment including blood pressure, BMI and smoking status and regular review thereafter.

Community pharmacists at Boots, LloydsPharmacy and Superdrug commonly provide adherence counselling and supply support for e‑prescriptions or electronic repeat prescriptions.

Indications & Expanded Uses

Patients often want to use the combined pill for acne, irregular periods or heavy cramps.

The licensed indication for levonorgestrel + ethinyl estradiol is oral contraception only; it is not approved as emergency contraception.

Some UK clinicians prescribe combined pills off‑label for cycle regularity, dysmenorrhoea or acne, with documentation and justification recorded in primary‑care notes.

Private clinics may offer the pill for these symptomatic indications after informed consent and explanation that these are secondary, off‑label benefits.

Contraindicated uses include post‑menopausal hormone therapy and treatment of menopausal symptoms; the product is not indicated for those purposes.

• Licensed Indication: Oral contraception only.
• Common Off‑Label Uses: Cycle regularity, dysmenorrhoea, acne (document and justify).

Composition & Brand Landscape

People still search for Alesse specifically, even when generics are dispensed.

The active ingredients are levonorgestrel and ethinyl estradiol, classified under ATC code G03AA07 as a fixed combined systemic hormonal contraceptive.

Typical Alesse strengths for the common 21/28 presentations are 0.1 mg levonorgestrel plus 0.02 mg ethinyl estradiol per active tablet.

Packaging formats include Alesse 21 (21 active pink tablets) and Alesse 28 (21 active pink tablets plus 7 placebo white tablets).

Original manufacture was by Pfizer/Wyeth; generics are widely available from Apotex, Teva and Sandoz.

Contraindications & Special Precautions

Safety checks before starting matter to reduce risk of serious harm.

Absolute contraindications in the product information and UK guidance include active thromboembolic disease (DVT/PE), history of stroke or coronary artery disease, migraines with aura, current breast cancer, uncontrolled hypertension, diabetes with vascular complications and severe hepatic impairment.

Relative cautions include obesity (BMI over 30), heavy smoking (more than 15 cigarettes a day, especially over age 35), family history of VTE, gallbladder disease and chronic renal impairment.

Clinicians must assess baseline blood pressure, BMI, smoking status and relevant family history before issuing an NHS prescription and record counselling on VTE warning signs.

• Immediate Red Flags: Unexplained leg pain, swelling, sudden chest pain or breathlessness, severe headache with visual disturbance.
• Screening Checklist: BP, BMI, smoking status, personal/family VTE history, migraine history, liver disease.

Dosage Guidelines

Common practical questions are about how to start and what to do if a pill is missed.

Standard regimen is one active tablet daily for 21 days followed by 7 days placebo in 28‑day packs, or 21 days active then 7 days no tablets in 21‑tablet packs, then repeat.

Adolescents who have reached menarche use standard adult dosing; the pill is not indicated before menarche or after menopause.

The product is contraindicated in severe hepatic impairment and caution is advised in mild–moderate hepatic impairment; use is not recommended for renal failure.

Missed‑dose instructions per product guidance are simple and clear.

• 1 active tablet missed: take as soon as remembered, even if two tablets are taken in one day; continue pack as normal.
• 2 or more active tablets missed: take the most recent missed tablet ASAP, discard the others, continue and use backup contraception for seven days.

Interactions Overview

Patients frequently ask whether antibiotics or herbal remedies will stop the pill working.

Drugs that induce hepatic enzymes can reduce plasma levels of ethinyl estradiol and levonorgestrel and may decrease contraceptive efficacy.

High‑risk interacting medicines include certain anticonvulsants, rifampicin and some antiretrovirals; these may necessitate alternative contraception or additional barrier methods.

Rifampicin is a documented antibiotic interaction with contraceptive failure risk; routine short courses of most other antibiotics have lower interaction evidence but patients should be counselled.

Herbal remedies such as St John’s wort can reduce plasma levels and should be avoided during combined pill use.

• High‑Risk Interactors: Carbamazepine, phenobarbital, phenytoin, rifampicin, some protease inhibitors and non‑nucleoside reverse transcriptase inhibitors.
• Mechanisms: Enzyme induction lowers hormone levels; protein binding changes are less relevant for these steroids.

Cultural Perceptions & Patient Habits

Many users look for reassurance about side effects they read about online.

UK patient forums such as Patient.info and Mumsnet and sexual health surveys show strong trust in pharmacist counselling and frequent use of NHS 111 or local sexual health clinics for urgent questions.

Brand recognition persists, with many patients searching familiar names such as Alesse even when dispensed generics like Aviane or Altavera.

Confidentiality, rapid access via walk‑in sexual health clinics, and online telemedicine with e‑prescribing are particularly valued by younger users seeking contraception.

• Common Patient Concerns: unscheduled bleeding, mood changes, perceived weight change.
• Support Channels: GP, community pharmacy, sexual health clinic, NHS 111, online providers.

Availability & Pricing Patterns

Patients need to know where to collect the pill and what it might cost regionally.

In the UK levonorgestrel + ethinyl estradiol products are prescription‑only and are widely stocked by major pharmacy chains and NHS sexual health services.

England has standard prescription charges for items, while Scotland, Wales and Northern Ireland provide free NHS prescriptions; this regional policy affects whether patients seek private online suppliers or NHS repeats.

Online pharmacies and telemedicine services supply generics under clinician assessment and e‑prescription pathways; in our online pharmacy, alesse is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.

Comparable Medicines And Preferences

Clinicians often choose between several combined pills depending on risk profile and tolerance.

Alternatives on NHS formularies include other low‑dose combined pills such as Microgynon, Marvelon and Seasonique, which differ in progestogen or dosing schedules.

Levonorgestrel‑containing combined oral contraceptives are frequently preferred where a lower VTE risk profile is desired compared with some newer progestogens, although individual side‑effect tolerance remains the deciding factor.

Decision aids should consider efficacy, side‑effect profiles, metabolic concerns and cost or availability on local formularies.

Frequently Asked Questions

1. Can I get Alesse on the NHS?

   Yes; levonorgestrel + ethinyl estradiol preparations are prescription‑only and may be supplied via NHS prescriptions and sexual health clinics, though brand availability can vary and generics are commonly dispensed.

2. What if I miss 2 tablets?

   Take the most recent missed tablet as soon as possible, discard other missed tablets, continue the pack and use backup contraception for seven days as per SPC missed‑pill guidance.

3. Is it safe if I have migraines?

   Migraines with aura are an absolute contraindication to combined pills; consult your GP or clinic for alternative contraception.

4. Will it affect fertility long‑term?

   Fertility typically returns after stopping combined oral contraceptives; there is no evidence that levonorgestrel + ethinyl estradiol causes long‑term infertility.

Guidelines For Proper Use

Pharmacists should follow a concise, documented counselling routine at supply.

Confirm the indication and screen for absolute and relative contraindications including smoking status, BMI, personal and family VTE history and migraine history.

Explain dosing clearly: one active tablet daily for 21 days then seven days placebo for 28‑day packs, and outline missed‑pill steps and the need for backup contraception when required.

Discuss interactions such as enzyme inducers and St John’s wort, and review VTE warning signs with the patient.

Document counselling in patient records and signpost to NHS online resources and the MHRA Yellow Card scheme for adverse‑event reporting.

• Red‑Flag Symptoms: Sudden breathlessness, chest pain, unilateral leg swelling, severe unexplained headache with visual changes.
• Follow‑Up: Offer a review at 4–12 weeks to assess tolerance and adherence.

Delivery Across United Kingdom